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Background and Objectives. The detection of PML-RAR
by reverse transcription (RT) polymerase chain reaction
(PCR) in acute promyelocytic leukemia (APL) patients
who are in hematologic remission influences therapeutic
decision making in several trials. In the light of this, the
Spanish group has recently designed an external quality
assessment program (EQAP) of RT-PCR detection of PML-
RAR, which includes a study of sensitivity of the partici-
pating laboratories.
Design and Methods. Eighteen laboratories were involved
in the program. Ten laboratories followed the method of
Biondi et al.,4  5 employed that of Borrow et al.10 and the
3 remaining used other protocols. The sensitivity was
studied in five rounds of quality control. The first two
shipments consisted of dilutions of NB4 RNA into non-
APL RNA. The third round consisted of serial dilutions of
the NB4 cell line into HL60 cells. The fourth and five
rounds consisted of plasmid dilutions containing the bcr1
and bcr3 PML-RAR isoforms.
Results. The results showed that the distinct methods
allow detection of the PML-RAR hybrid up to a dilution of
10–4, and exceptionally, up to 10–5. The laboratories fol-
lowing the method of Biondi et al. usually detected the
10–3 dilution and less frequently the 10–4 one, whereas
those using other methods usually detected PML-RAR
transcript in the 10–4 dilution, and less commonly in the
10–5 dilution. However, each of the PCR methods used by
EQAP participating laboratories successfully detected at
least 50 copies of PML-RARα fusion transcript in plas-
mid dilution controls.
Interpretation and Conclusions. The results point to het-
erogeneous sensitivity amongst participating laborato-
ries. This may reflect differences in methodology,
although variations in sample quality may also account
for discrepant findings.
©2001, Ferrata Storti Foundation
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Reverse-transcription polymerase chain reaction(RT-PCR) has been increasingly employed as arapid and powerful tool for detecting genetic
lesions in leukemia. Moreover, it represents the most
sensitive method to identify minimal residual disease
(MRD) in patients who are in clinical remission after
treatment. Compared to RT-PCR assays used to iden-
tify other gene rearrangements, the RT-PCR tech-
niques employed for detecting the acute promyelo-
cytic leukemia (APL)-specific PML-RAR fusion show
inferior sensitivity.1 In fact, reported PML-RAR ampli-
fication methods usually reach a 10-4 dilution detec-
tion threshold, i.e. one or two logs below the sensi-
tivity reported for the BCR-ABL2 and AML1-ETO3 RT-
PCR assays used for chronic myeloid leukemia and
t(8;21) acute myeloid leukemia, respectively. Howev-
er, a certain degree of heterogeneity in sensitivity is
also found between different APL studies. For exam-
ple, two of the most widely adopted assays,  the tech-
niques originally described by Biondi et al.4 and Chen
et al.5 differ by as much as one log in their sensitivi-
ty, with reported detection levels of 10–4 for the bcr1
transcript using the former method  and 10–5 for long
and short transcripts using the latter.
The sensitivity of the PML-RAR RT-PCR assays used
for MRD evaluation appears to be extremely impor-
tant in clinical practice. Using a technique with a 10–4
detection threshold, the Italian Cooperative Group
GIMEMA reported in a prospective monitoring study
that virtually all APL patients who converted from
PCR-negative to positive during clinical remission
underwent hematologic relapse after a median time
of 3 months.6 As a consequence of such findings,
patients enrolled in the GIMEMA study who show
PCR-positivity for PML-RAR (confirmed in two suc-
cessive marrow samples) are now defined as having
molecular relapse and given anticipated salvage ther-
apy. By contrast, using a more sensitive assay Tobal
et al.7 found that, like patients with other leukemias,
some APL patients in long-term remission and pre-
sumably cured may nevertheless show PCR-
detectable MRD.
In the light of these findings and because prospec-
tive monitoring was to be initiated in 1996 for
patients enrolled in the Spanish multicenter APL tri-
al, we designed at that time an external quality
assessment program (EQAP) for RT-PCR detection of
PML-RAR. The program originally involved only those
Spanish laboratories belonging to institutions partic-
ipating in the PETHEMA LPA-96 clinical trial, but was
subsequently extended to several other European lab-
oratories. The aims of the first part of the study, which
involved two rounds of quality control, were to eval-
uate the concordance of results between participat-
ing laboratories for diagnostic evaluation of the
fusion gene.8 The present analysis summarizes the
results of a further five rounds of quality control
designed to evaluate the sensitivity achieved by the
participating laboratories in PML-RARα detection. 
Design and Methods
The organization of the EQAP program was
described in a previous report.8 It basically consisted
of periodic shipments (one every semester) of a set of
control samples (between 4 and 7) to all participat-
ing laboratories. For each shipment round, one of the
laboratories involved in the program was responsible
for sample preparation, shipment in dry ice and deliv-
ery within 24 h to all other laboratories. The labora-
tory in charge of sample preparation and shipment
varied in each round and was excluded from sample
analysis. The results of RT-PCR analyses, to be done
blindly on numbered vials, were requested back with-
in 30 days from the date of shipment. As in the pre-
ceding rounds, participants were asked to fill in and
send back to the Co-ordinating Center (Laboratorio de
Biología Molecular, Hospital Universitario La Fe,
Valencia, Spain) the forms detailing the following: i)
condition of samples on arrival; ii) most relevant
technical aspects of the methodology used; iii) ampli-
fication results.
At present, the program includes a total of 18 lab-
oratories (Table 1), of which 14 belong to Spanish
Institutions and the remaining 4 to Centers in other
European countries (Italy, France, UK, and The Nether-
lands). 
Control  samples
Sensitivity experiments were performed in five suc-
cessive EQAP rounds (from the 4th to the 8th) which were
carried out during the period October 1998 (4th round)-
November 2000 (8th round).
In the 4th and 5th rounds, RNA samples of the APL cell
line NB4 were sent. In the 4th shipment the samples
consisted of 10-fold serial dilutions (10-2,10-3, 10-4) of
NB4 RNA into RNA obtained from blood mononuclear
cells of patients with chronic myeloid leukemia (CML)
(Table 2). Undiluted CML-derived RNA was also used as
a negative control in this round. The 5th shipment con-
sisted of undiluted NB4 RNA and 10-fold serial dilutions
(10-3 through 10-5) of NB4 RNA in RNA derived from the
Kasumi cell line. RNA was extracted by the phenol-chlo-
roform procedure as reported by Chomczynski and Sac-
chi.9
The 6th shipment consisted of cellular samples, each
one containing a total of 107 cells and including two sam-
ples at 10-2 and one at a 10-3 dilution of  NB4 into the
HL60 cell line. Positive and negative controls consisted of
107 undiluted NB4 and HL60 cells, respectively (Table 2). 
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The 7th shipment consisted of plasmid DNA con-
taining PCR amplification products of the bcr1 and
bcr3 PML-RAR isoforms (Table 2). These products
were obtained using the oligoprimers M2-R5 (for
bcr1) and M4-R5 (for bcr3) published by Biondi et
al.,4 and cloned in a plasmid vector PCRII-TOPO
(TOPO™ TA Cloning®, Invitrogen BV, 970 VT Gronin-
gen, The Netherlands). The samples included three
10-fold serial dilutions of the plasmids which con-
tained concentrations of 4,000, 400 and 40 plasmid
copies/µL of the bcr1 isoform, and, 2,500, 250, 25
plasmid copies/µL of the bcr3 isoform. A water sam-
ple was used in this shipment as the negative control. 
The 8th shipment consisted of serial  plasmid dilu-
tions containing a full length bcr1 insert into an
aqueous solution containing 1 g of salmon sperm
DNA at the following concentrations: 0 (reagent
blank), 50, 200, 800 and 10,000 plasmid copies/µL
(Table 2). In the 7th and 8th shipments, 1mL of control
material was used as template in the subsequent PCR
reaction.
Reverse transcriptase and PCR protocols 
The distinct methods followed between the 4th and
8th rounds of our EQAP are shown in Table 3. Ten lab-
oratories followed the procedure reported by Biondi
et al.,4 five laboratories used the protocol published by
Borrow et al.10 and each one of the three remaining
laboratories followed methods reported by Chen et
al.5 or Huang et al.,11 Miller et al.12 and Castaigne et
al.13 The majority of laboratories (14/18) amplified
RAR in parallel as the control gene as previously
described,4,5,10-13 including one which amplified PML
in addition according to the method of Borrow et al.10
The remaining 4 laboratories which all used the PML-
RARα assay described by Biondi et al. used alterna-
tive control gene assays; 3 amplified ABL using
primers of Cross et al.2 and one used AML1 employ-
ing primers reported by Satake et al.14
The main differences between these methods in
terms of enzyme type and incubation time for the
reverse transcription step are reported in Table 3.
The 7th shipment, which consisted of plasmid-
cloned PCR products, was restricted to laboratories
with suitable primers to amplify the cloned insert. In
this shipment round, the RT protocol was irrelevant
since DNA samples were tested. In this EQAP round,
three of the participating laboratories followed
Biondi’s method,4 one performed Borrow’s method10
modified by the introduction of the P6 primer as
reported by Gallagher et al.15 The remaining three lab-
oratories followed the method described by Chen,5
the BIOMED-1 European Concerted Action16 and the
real-time PCR method of Gabert et al.17
Table 1. List of participating laboratories.
Person responsible Hospital City
Dr. D Colomer Clínico de Barcelona Barcelona
Dr. J Roman Reina Sofía Cordoba
Dr.  MT Gómez H Gran Canaria Dr. Negrin Las Palmas de 
Gran Canaria
Dr. D Grimwade University College and Guy's Hospital London
Dr. E Anguita Universitario San Carlos Madrid
Dr. R Bornstein Doce de Octubre Madrid
Dr. P Cabello H Ramón y Cajal Madrid
Dr. J Benítez C.to Nac. de Investigaciones Oncológicas Madrid
Dr. J.A. García-Marco Puerta de Hierro Madrid
Dr. JL Vizmanos Universidad de Navarra Pamplona
Dr. Ch Chomienne Hôpital Saint-Louis Paris
Dr. D Diverio Universitá degli Studi "La Sapienza" Rome
Dr. J Jansen Erasmus Universiteit Rotterdam
Dr. M Gonzalez Clínico Universitario Salamanca
Dr. M Delgado H Marques de Valdecilla Santander
Dr JM De Blas Virgen del Rocio Sevilla
Dr. I Marugan Clínico Universitario Valencia
Dr. E Barragan Universitario La Fe Valencia
Table 2. Participation and study feasibility.
Round Composition Number Number of labs Validated/ Reasons for exclusion
of samples reporting results reported results
4th NB4 RNA diluted in CML RNA 4 15 52/60 Degraded RNA due to poor shipment conditions (n=4) or
delayed analysis (n=4).
5th NB4 RNA diluted in Kasumi RNA 4 15 56/60 Degraded RNA (n=4)
6th NB4 cells diluted in HL60 cells 5 13 65/65
7th Plasmid containing PCR bcr1 or bcr3 inserts 7 8 49/56 Contamination strongly suspected due to amplification of bcr3
PML-RAR in all controls plus water sample
8th Plasmid containing a bcr1 full length insert 5 16 80/80
CML= Chronic myeloid leukemia.  Reported results: refers to the total number of results returned to the co-ordinating laboratory;  Validated results: refers to the number of
evaluable results that were included in the final analysis. Reasons for sample exclusion are detailed in the right-hand column. 
Variability in PML-RAR levels detected in an external quality control program 573
haematologica vol. 86(6):june 2001
Distinct from plasmids sent out in the previous
EQAP round, the plasmid sent during the 8th shipment
contained a full length bcr1 insert, and all the 16 par-
ticipating laboratories had primers capable of ampli-
fying the cloned fragment. 
Results
Participation and study feasibility 
The results of study feasibility are summarized in
Table 2. The Co-ordinating Center received data from
15 laboratories in the 4th EQAP. Results from 8/60
samples were excluded, because of delayed delivery
and RNA degradation or delayed analysis of the sam-
ples. Similarly, results from 4 samples received by 1
laboratory were excluded from the next round in
which  60 results were received from 15 laboratories.
In the 6th shipment EQAP data were received from 13
laboratories and in the 7th shipment, which consisted
of plasmid DNA controls, only 8 laboratories with
suitable primer sets participated with data from one
laboratory (7 results) excluded because of sample
contamination (Table 2). In the 8th shipment, which
consisted of plasmid DNA containing a full length
bcr1 isoform insert, the results from 16 laboratories
were reported.
Sensitivity of PML-RAR detection reported
by the laboratories
The results of PML-RAR analysis in RNA samples
(4th and 5th EQAP shipments) are given in Table 4.
These show that almost all laboratories detected the
transcript in the 10-2 dilution of the NB4 cell line.
Eighteen out of 27 (67%) samples containing the NB4
10-3 dilution were reported as PML-RAR positive. Pos-
itive results were also reported in 5/13 non-APL con-
trols. 
With respect to the analysis of cell dilution samples
(Table 4, NB4 cells), the results were comparable to
those obtained with RNA samples. Hence, PML-RAR
was detected by all laboratories in the 10-2 dilution,
whereas some centers (4/13) reported absence of
amplification in the 10-3 NB4 dilution. None of the
laboratories reported positive PML-RAR detection in
the HL60 cell line negative control. As to the distinc-
tion of the PML-RAR isoform, in 10/110 results in
which PML-RAR fusion transcripts were detected the
PML breakpoint was erroneously reported as bcr3
rather than bcr1. Five different laboratories reported
these erroneous results. In four of them the misclass-
ification was restricted to one sample of the 5th ship-
ment. However, for the remaining laboratory the
results most likely reflected technical problems since
the misclassification affected 5 samples, one from
the 4th shipment and 4 from the 5th. Moreover, this
laboratory also reported a positive result in the neg-
ative control, which was classified as bcr3. These
problems were addressed in subsequent EQAP rounds,
with the latter laboratory classifying all PML break-
points correctly and reporting no false positives.
Table 3.  Reverse transcription and PCR methods of partic-
ipating laboratories.
Methods Reverse transcriptase Incubation time
AMV MMLV <1h (15-50 min) =1 h (60-90 min)
Biondi et al. 2 8 6 4
Borrow et al. 4 1 1 4
Huang, Miller, Castaigne — 3 1 2
The figures within the table relate to the number of laboratories using a particular
RT-PCR method.
Abbreviations:  AMV, Avian myelomatosis virus reverse transcriptase; 
MMLV, Moloney murine leukemia virus reverse transcriptase.
Table 4. Results of NB4 RNA and cellular samples.
Methods RNA NB4 cells (4th and 5th shipments) NB4 cells (6th shipment)
NB4 100 NB4 10-2 NB4 10-3 NB4 10-4 NB4 10-5 No APL 107 NB4 10-2 NB4 10-3 NB4 107 HL60
Biondi et al.
PML-RAR positive/total (%) L 7/7 (100) 6/7 (86) 6/13 (46) 5/14 (36) 1/7 (14) 1/7 (14) 6/6 (100) 12/12 (100) 4/6 (67) 0/6 (0)
Borrow et al.
PML-RAR positive/total (%) L 5/5 (100) 4/4 (100) 8/9 (88) 6/9 (66) 3/5 (60) 3/4 (75) 5/5 (100) 10/10 (100) 4/5 (80) 0/5 (0)
Miller, Huang & Castaigne et al.
PML-RAR positive/total (%) 2/2 (100) 2/2 (100) 4/5 (80) 3/4 (75) 0/2 (0) 1/2 (50) 2/2 (100) 4/4 (100) 1/2 (50) 0/2 (0)
Overall results
PML-RAR positive/total (%) 14/14 (100) 12/13 (92) 18/27 (67) 14/27 (52) 4/14 (29) 5/13 (38) 13/13( 100) 26/26 (100) 9/13 (69) 0/13 (0)
The figures within the table relate to the number of results reported.
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Sensitivity of the PML-RAR methods
The laboratories that followed Biondi’s method4
reported detection thresholds between 10-3 and 10-4.
In fact, PML-RAR was detected in 6/13 and 5/14 sam-
ples for the 10-3 and the 10-4 RNA dilutions, respec-
tively (Table 4). A false positive result in the non-APL
RNA was recorded in 1 of 7 samples for laboratories
using this assay. In the EQAP round involving cellular
samples (6th), 4/6 laboratories using this method
detected the 10-3 dilution of NB4 and no false posi-
tives were obtained (Table 4). 
No difference in PML-RAR detection was observed
when laboratories using Biondi’s method were
grouped according to the incubation time of the
reverse transcription (RT) step (1h  vs.< 1h). 
A higher proportion of PML-RAR positive results
was recorded by laboratories using Borrow’s method
in the 10-4 and 10-5 RNA dilutions (6/9 and 3/5,
respectively, Table 4). However, a higher proportion of
positive results (3/4) in the negative control was also
reported by the laboratories using this assay (Table 4).
In the analysis of cellular samples 4/5 laboratories
detected the 10-3 dilution of NB4 (Table 4). For this
method most of the participants (4 of 5 laboratories)
performed RT with incubation times longer than 1 h.
The results of the 3 remaining laboratories using
alternative techniques11-13 were similar in terms of
sensitivity to the ones which followed Borrow’s
method.10 Hence, a high proportion of positive results
was recorded up to the 10-4 dilution (Table 4).
Absolute sensitivity studies with plasmid
DNA
As shown in Table 5, all laboratories participating
in the 7th round amplified and correctly identified the
PML-RAR fusion gene in the more concentrated plas-
mid controls containing 4,000 copies of the bcr1 plas-
mid/µL and 2,500 copies of the bcr3 plasmid/µL. Four
out of 7 laboratories could amplify the bcr1 plasmid
at the concentration of 400 copies/µL and 3 of 7
detected the hybrid transcript in the control con-
taining 250 plasmid copies/µL of the bcr3 isoform;
however one laboratory erroneously identified the
bcr3 fusion gene as bcr1. Only one of seven labora-
tories reported amplification of the bcr1 plasmid at
the concentration of 40 copiesµ/L, but incorrectly
identified the fusion gene as bcr3, whereas 2 of 7
laboratories amplified and correctly identified the
bcr3 plasmid at the concentration of 25 copies/µL
(Table 5).
In the 8th shipment, all the participating laborato-
ries (16/16) detected the PML-RAR rearrangement in
the control with the lowest bcr1 concentration (50
plasmid copies/µL) (Table 5). As to the negative con-
trol, most of the laboratories (14/16) reported it cor-
rectly as negative, one reported it as positive and the
remaining laboratory as equivocal. No difference
could be found when the data reported were classi-
fied according  to the distinct methods employed by
participating laboratories. Whilst the PML-RAR fusion
gene copy numbers contained within plasmid dilution
controls distributed in the 7th and 8th quality control
rounds were independently confirmed by real-time
PCR analysis performed in the co-ordinating labora-
tory against common plasmid standard curves, the
sensitivity reported in the 7th round was worse than
in the 8th. This may be accounted for by a variable
reduction in PML-RAR copy number concentration
due to degradation of plasmid DNA or absorptive
effects of the sample tubes occurring during transit
or storage prior to analysis. 
Discussion 
In this study on the detection of the APL-specific
PML-RAR hybrid at various dilutions, we observed
some important discrepancies which may result from
logistic and technical problems. For example, it is pos-
sible that a heterogeneous degree of RNA degrada-
tion occurred in the various shipments. Moreover, no
hybridization step was required to confirm the speci-
ficity of amplified products. Besides these caveats,
this study confirms the limited sensitivity of the
methods commonly used to detect the PML-RAR
rearrangement. Hence in the analysis of NB4 RNA
samples, most laboratories amplified the 10-2 dilu-
tion, whereas a significant number were not able to
detect the rearrangement at a 10-3 dilution, and few
detected it at 10-4. 
The data obtained from the present study suggest
that the sensitivity threshold of 10-4 originally report-
ed by both Biondi et al.4 and Borrow et al.10 is not
Table 5. Results of the plasmid controls.
Shipment Controls Concentration copies/µL PML-RAR+/total (%)
7th shipment bcr3 plasmid 2,500 7/7(100)
250 3/7(43) 
25 2/7(29) 
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widely reproduced in the setting of a multi-laborato-
ry study, as in the majority of cases a lower sensitiv-
ity was obtained, particularly using Biondi’s proto-
col.4 Although participating laboratories were
requested to evaluate sample quality on arrival and
successful control gene amplification had to be
obtained to validate the results, it is possible that
sample shipment to several laboratories might have
altered PML-RAR stability. 
As to the reverse transcriptase phase, the limited
number of results did not permit consideration of all
the factors that might influence efficiency of this step
(primer and RT enzyme used, inclusion of a denatu-
ration step, and incubation time). However, no rele-
vant differences were recorded among the laborato-
ries that performed a prolonged RT incubation ( =1h)
versus those laboratories which adopted a shorter
time (< 1h). 
As shown in Table 4, a high incidence of false pos-
itivity was found analyzing non-APL RNA samples,
which were most frequently reported by laboratories
using Borrow’s method. The most likely explanation
for this was introduction of low levels of contamina-
tion by the laboratory preparing the samples. This
hypothesis is supported by the fact that in the 6th
round, that consisted of cellular samples requiring
less laboratory manipulations, no positive result was
recorded in the HL60 cell sample (Table 4). Distribu-
tion of cellular samples as quality control materials
also had the advantage that they permitted evalua-
tion of additional phases of sample processing,
including RNA extraction, as well as the RT and PCR
steps, which are likely to have an impact on the sen-
sitivity of RT-PCR assays undertaken in a clinical set-
ting. Plasmid dilution standards afford the opportu-
nity to consider the sensitivities of particular PCR
primer sets in isolation, without potentially con-
founding influences generated by inter-laboratory
differences in other aspects of the RT-PCR protocol.
Our experience with plasmid solutions suggests that
they cannot invariably be relied upon to provide sta-
ble controls for quality control purposes. Whilst all
laboratories successfully detected 50 copies of bcr1
PML-RAR transcript in the 8th round, only 1/7 detect-
ed 40 copies in the preceding round. This discrepan-
cy in sensitivity is likely to reflect degradation or
absorption of plasmid DNAs distributed in the 7th
shipment prior to the point of analysis.
In conclusion, our external quality control study on
detection of the PML-RAR fusion transcript by RT-
PCR revealed heterogeneous sensitivities amongst
participating laboratories. This is likely to reflect the
inherent instability of materials sent for molecular
analyses, but may also be accounted for in part by dif-
ferences between RT and PCR protocols employed by
participating laboratories. These issues are important
to take into account in the setting of large multicen-
ter studies. It is expected that the quantification of
PML-RAR transcripts with specific and highly sensi-
tive quantitative methods developed using real-time
PCR equipment17,18 will, in the near future, offer ade-
quate standardization of sensitivity for optimal com-
parison of results obtained in clinical trials. 
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Potential implications for clinical practice
The PML-RAR RT-PCR assay used for minimal resid-
ual disease evaluation in APL is critically important
for clinical practice, since results are used to guide
therapy.19-22 The standardization of methods and
reporting of results of assays used for molecular diag-
nosis and minimal residual disease monitoring in
leukemia will facilitate comparison of outcome
between different clinical trials; external quality
assessment programs including large numbers of par-
ticipating laboratories play an essential role in this
process and in the provision of reliable results upon
which patient management decisions may be based.
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